Slide 1: Q2 2026 Financial Results Conference Call
Veeco Instruments Q2 2026 Financial Results Conference Call August 5th, 2026 1
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is not intended to and shall not constitute an offer to purchase or the solicitation of an offer to buy or sell any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unla
Slide 3: CEO Overview
CEO Overview Bill Miller, Ph.D. 3
Slide 4: Q2 2026 Highlights
Q2 2026 Highlights Key Takeaways 1. Strong performance and street beat Revenue 2. Acceleration of order momentum across all major $193M end markets; strengthening 2027 visibility Non-GAAP • Secured $200M in Advanced Packaging orders Operating Income $23M 3. Executing manufacturing expansion plan; de
Slide 5: Veeco's Critical Role in Semi Manufacturing & SAM Expansion
Veeco’s Critical Role in Semi Manufacturing & SAM Expansion FRONT END Representative Process Steps BACK END Ion Implant Anneal Inspection Adv. Deposition Lithography Etch Packaging IBD IBD Wet LSA NSA Processing Litho 300 EUV New products Driving revenue Key Process 2026 2030 Total Served Available
Slide 6: Compound Semi Projected SAM Growth
Compound Semi Projected SAM Growth Total Served Available Market Key Driver 2026 2030 Silicon • Lumina® MOCVD InP platform ~$2.0B Photonics • WaferEtch® and WaferStorm® systems ~$300M ~$700M Projected (InP Lasers) • Spector® IBD for laser diode facets coatings ~15% CAGR ~$1.0B • Lumina® MOCVD platfo
Slide 7: Veeco's Critical Role in Compound Semi: Indium Phosphide Laser Solutions
Veeco’s Critical Role in Compound Semi: Indium Phosphide Laser Solutions Repeat cycle depending on device Anneal / Laser Facet Epitaxy Patterning Etch Metallization Cleave Coating WaferEtch® / Lumina® MOCVD WaferStorm® Spector® Wet Processing InP Platform Ion Beam Deposition Size of bubble represent
Slide 8: CFO Overview
CFO Overview John Kiernan vee
Slide 9: Q2 2026 Revenue by Market & Region
Q2 2026 Revenue by Market & Region Revenue by Market Revenue by Region Scientific & ROW is negligible Other 10% 11% United States Compound 31% Semiconductor United States $193M 11% APAC 36% Data China 68% Storage 25% Semiconductor 8% EMEA & ROW Revenue Trend ($M) Q2 25 Q1 26 Q2 26 Revenue Trend ($M)
Slide 10: Q2 2026 Operating Results
Q2 2026 Operating Results GAAP Non-GAAP Non-GAAP In millions Q2 26 Guidance (except per share amounts) Q1 26 Q2 26 Q1 26 Q2 26 (as of May 5th, 2026) Revenue $158.3 $193.5 $158.3 $193.5 $170M - $190M Gross Profit 55.8 74.8 57.3 76.4 Gross Margin 35.3% 38.7% 36.2% 39.5% 38% - 40% Operating Expenses 58
Slide 11: Balance Sheet and Cash Flow Highlights
Balance Sheet and Cash Flow Highlights $ millions Q1 2026 Q2 2026 Cash & Short-Term Investments 383 429 Accounts Receivable 151 148 Inventories 282 292 Accounts Payable 60 57 Long-Term Debt 226 227 Cash Flow from Operations 8 51 Capital Expenditures 5 4 DSO (days) 86 69 DIO (days) 245 218 DPO (days)
Slide 12: Q3 & FY 2026 Outlook
Q3 & FY 2026 Outlook Q3 2026 FY 2026 GAAP Non-GAAP GAAP Non-GAAP Revenue $200M - $220M $200M - $220M $780M - $810M $780M - $810M Gross Margin 40% - 42% 41% - 42% 39% - 41% 40% - 42% Operating Expenses $66M - $67M $57M - $58M $253M - $263M $215M - $225M Net Income $14M – $23M $23M - $33M $52M - $68M
Slide 13: Q&A
Q&A e€ec
Slide 14: Backup & Financial Tables
Backup & Financial Tables vee
Slide 15: Historical Revenue by End-Market
Historical Revenue by End-Market $M 2022 2023 2024 2025 2026 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Semi 369.4 93.1 106.3 98.2 115.2 412.7 120.4 109.9 124.1 112.1 466.6 123.8 123.9 118.3 110.5 476.6 109.0 130.7 Compound 121.2 21.2 24.1 25.7 16.3 87.3 21.0 18.2 15.6 22.8 77.6 14.4 14.2
Slide 16: 2029 Convertible Notes Outstanding
2029 Convertible Notes Outstanding As of June 30, 2026 Effect of Convertible Notes on Diluted EPS (GAAP and Non-GAAP)* Average Stock Price per Incremental Dilutive Principal Carrying Annual Annual Initial Common Share Shares (in thousands) Coupon Cash Non-Cash Conversion Convertible Amount Value Int
Slide 17: Note on Reconciliation Tables
Note on Reconciliation Tables These tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These Non-GAAP financial measures exclude items such as: sh
Slide 18: Supplemental Information—GAAP to Non-GAAP Reconciliation
Supplemental Information—GAAP to Non-GAAP Reconciliation $ millions, except per share amounts Q1 26 Q2 26 $ millions Q1 26 Q2 26 GAAP Basic weighted average shares 60.4 61.1 Net sales $158.3 $193.5 GAAP Diluted weighted average shares 60.4 66.8 GAAP gross profit 55.8 74.8 GAAP Basic EPS ($0.01) $0.1
Slide 19: Q2 2026 Actual: GAAP to Non-GAAP Reconciliation
Q2 2026 Actual: GAAP to Non-GAAP Reconciliation $ millions Non-GAAP Adjustments Share-Based GAAP Compensation Amortization Other Non-GAAP Net Sales $193.5 $193.5 Gross Profit 74.8 1.6 — — 76.4 Gross Margin 38.7% 39.5% Operating Expenses $63.0 (7.6) (0.6) (1.5) $53.3 Operating Income $11.9 9.2 0.6 1.
Slide 20: Q3 2026 Guidance
Q3 2026 Guidance ($ millions, except per share amounts) Reconciliation of GAAP to non-GAAP Financial Data Non-GAAP Adjustments Share-Based GAAP Compensation Amortization Other Non-GAAP Net Sales $200–$220 $200–$220 Gross Profit 80–92 1 — — 82–93 Gross Margin 40%–42% 41%–42% Operating Expenses $66–$6
Slide 21: FY 2026 Guidance
FY 2026 Guidance ($ millions, except per share amounts) Reconciliation of GAAP to non-GAAP Financial Data Non-GAAP Adjustments Share-Based GAAP Compensation Amortization Other Non-GAAP Net Sales $780–$810 $780–$810 Gross Profit 306–334 6 — — 312–340 Gross Margin 39%–41% 40%–42% Operating Expenses $2